Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immune checkpoint inhibitors have limitations in efficacy and toxicity across cancers.
• Targeted immunotherapies offer a more selective approach to cancer treatment.
• T-cell engagers (TCEs) and antibody-drug conjugates (ADCs) are emerging strategies.

Purpose of the Study:

• To review the advancements in targeted immunotherapies, including TCEs and ADCs.
• To discuss the efficacy, toxicities, and influencing factors of these novel therapies.
• To highlight the potential for a new era of precision immuno-oncology.

Main Methods:

• Review of current literature on TCEs and ADCs in cancer therapy.
• Analysis of clinical successes, challenges, and emerging approaches.
• Discussion of biomarkers, combinations, and resistance mechanisms.

Main Results:

• TCEs show success in hematologic malignancies and promise in solid tumors (e.g., tebentafusp, tarlatamab).
• ADC-checkpoint inhibitor combinations demonstrate significant survival gains (e.g., urothelial carcinoma).
• Efficacy is influenced by antigen density, heterogeneity, microenvironment, and sequencing.

Conclusions:

• TCEs and ADCs represent a significant step towards precision immuno-oncology.
• Further research is needed for improved biomarkers, rational combinations, and understanding resistance.
• These targeted strategies aim to enhance efficacy while mitigating treatment-related toxicities.